Literature DB >> 8888811

Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate.

L L Hsu1, A E Evans, G J D'Angio.   

Abstract

Infants with neuroblastoma (NBL) frequently present as stage 4s and overall, such patients have a good prognosis. However, not all survive, and neonates with hepatomegaly are particularly at risk. We therefore reviewed our 4s experience, the objective being to identify lethal patterns of disease progression. The specific aims of this work were (1) to develop a semiquantitative scoring system based on the severity of signs and symptoms that alone or in combination presaged a fatal outcome, and (2) to determine if early intervention could reverse life-threatening disease. Thirty-five patients were seen over a period of 50 years. The signs and symptoms of organ distress caused by hepatomegaly occurred in the lungs, kidneys, gastrointestinal tract (GI), the inferior vena cava (IVC), and the liver. A scoring scale reflecting organ compromise was developed, the scores ranging from 0 (0 compromise) to 10 (all 5 systems showing evidence of impairment). Scores were derived for 32 of 35 patients; 13 were 4 weeks old or under (neonates) when first seen, and 19 were aged 1-12 months (infants). Neonates were more likely than infants to develop increasing symptomatology (50% versus 25%) and were more likely to die when a score of 2 or more developed. None of the 6 neonates who did so survived despite treatment, compared with three of four infants. Early intervention is recommended: (1) for 4s neonates who develop a score of 1 and (2) for older infants with a score > or = 2.

Entities:  

Mesh:

Year:  1996        PMID: 8888811     DOI: 10.1002/(SICI)1096-911X(199612)27:6<521::AID-MPO3>3.0.CO;2-N

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  13 in total

Review 1.  Neonatal tumours.

Authors:  Kokila Lakhoo; Helen Sowerbutts
Journal:  Pediatr Surg Int       Date:  2010-10-19       Impact factor: 1.827

Review 2.  [Neuroblastoma].

Authors:  Victoria Castel; Adela Cañete; Rosa Noguera; Samuel Navarro; Silvestre Oltra
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

Review 3.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

4.  Neonatal neuroblastoma.

Authors:  J Moppett; I Haddadin; A B Foot
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-09       Impact factor: 5.747

5.  A single center clinical analysis of children with neuroblastoma.

Authors:  Jing-Bo Shao; Zheng-Hua Lu; Wen-Yan Huang; Zhi-Bao Lv; Hui Jiang
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

6.  Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.

Authors:  Clare J Twist; Arlene Naranjo; Mary Lou Schmidt; Sheena C Tenney; Susan L Cohn; Holly J Meany; Peter Mattei; E Stanton Adkins; Hiroyuki Shimada; Wendy B London; Julie R Park; Katherine K Matthay; John M Maris
Journal:  J Clin Oncol       Date:  2018-11-16       Impact factor: 44.544

7.  Resection of primary tumor in stage 4S neuroblastoma: a second study by the Italian Neuroblastoma Group.

Authors:  Stefano Avanzini; Isabella Buffoni; Anna Rita Gigliotti; Stefano Parodi; Irene Paraboschi; Alessandro Inserra; Patrizia Dall'Igna; Anna Maria Fagnani; Giuseppe Martucciello; Mario Lima; Umberto Caccioppoli; Alberto Garaventa; Massimo Conte; Claudio Granata; Angela Rita Sementa; Elisa Tirtei; Giovanni Erminio; Bruno De Bernardi
Journal:  Pediatr Surg Int       Date:  2020-10-29       Impact factor: 1.827

8.  Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?

Authors:  A Di Cataldo; A Agodi; J Balaguer; A Garaventa; M Barchitta; V Segura; M Bianchi; V Castel; A Castellano; S Cesaro; J M Couselo; O Cruz; P D'Angelo; B De Bernardi; J Donat; N G de Andoin; M I Hernandez; M La Spina; M Lillo; R Lopez-Almaraz; R Luksch; S Mastrangelo; E Mateos; J Molina; C Moscheo; R Mura; F Porta; G Russo; A Tondo; M Torrent; S Vetrella; J A Villegas; E Viscardi; G A Zanazzo; A Cañete
Journal:  Clin Transl Oncol       Date:  2016-04-04       Impact factor: 3.405

9.  Retrospective study of neuroblastoma in Chinese neonates from 1994 to 2011: an evaluation of diagnosis, treatments, and prognosis : a 10-year restrospective study of neonatal neuroblastoma.

Authors:  Yaodong Zhou; Kai Li; Shan Zheng; Lian Chen
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-05       Impact factor: 4.553

10.  Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.

Authors:  Asuka Kawano; Florette K Hazard; Bill Chiu; Arlene Naranjo; Brian LaBarre; Wendy B London; Michael D Hogarty; Susan L Cohn; John M Maris; Julie R Park; Julie M Gastier-Foster; Naohiko Ikegaki; Hiroyuki Shimada
Journal:  Am J Surg Pathol       Date:  2021-08-01       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.